QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 nateras-signatera-demonstrates-predictive-power-in-imvigor011-guiding-tecentriq-use-for-improved-bladder-cancer-outcomes

Data to be featured in Presidential Symposium at ESMOSignatera™ changes the paradigm by expanding the adjuvant decision window,...

 canaccord-genuity-maintains-buy-on-natera-maintains-200-price-target

Canaccord Genuity analyst Kyle Mikson maintains Natera (NASDAQ:NTRA) with a Buy and maintains $200 price target.

 natera-announces-publishes-signatera-validation-study-in-testicular-cancer-in-journal-of-clinical-oncology---precision-oncology

Largest ever ctDNA study in testicular cancer shows Signatera significantly outperformed standard of care tumor markers

 wells-fargo-initiates-coverage-on-natera-with-equal-weight-rating-announces-price-target-of-175

Wells Fargo analyst Brandon Couillard initiates coverage on Natera (NASDAQ:NTRA) with a Equal-Weight rating and announces Pr...

 neogenomics-gains-unexpected-win-as-court-rejects-natera-claims

NeoGenomics wins a North Carolina court ruling invalidating key Natera patents, clearing the way for its RaDaR ST assay and boo...

 natera-patent-claims-against-neogenomics-radar-v11-invalidated-company-weighs-appeal-further-enforcement

Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today provided an update regarding its int...

 natera-announces-activation-of-nrg-oncology-trial-archer-randomized-phase-iii-study-in-muscle-invasive-bladder-cancer

Randomized study aims to reduce treatment burden for patients and utilizes Signatera to monitor for disease recurrenceNatera, I...

 natera-released-topline-results-from-the-phase-3-imvigor011-trial-in-muscle-invasive-bladder-cancer-showing-that-signatera-positive-patients-treated-with-atezolizumab-tecentriq-had-statistically-significant-and-clinically-meaningful-improvements-in-disease-free-survival-and-overall-survival

The trial is sponsored by Genentech, a member of the Roche Group. IMvigor011 is the first prospective phase III study in muscle...

 stephens--co-reiterates-overweight-on-natera-maintains-183-price-target

Stephens & Co. analyst Mason Carrico reiterates Natera (NASDAQ:NTRA) with a Overweight and maintains $183 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION